Outcomes in Standard Risk Multiple Myeloma Identified via Gene Profiling

Share this content:
Outcomes in Standard Risk Multiple Myeloma Identified via Gene Profiling
Outcomes in Standard Risk Multiple Myeloma Identified via Gene Profiling

Gene profiling expression should be used to identify subsets of patients with standard risk multiple myeloma who, despite novel therapies and hematopoietic stem cell transplant (auto-HCT), have significantly shorter progression-free survival rates.1

Outcomes for patients with standard risk multiple myeloma have improved dramatically with the advent of novel treatments, with progression-free survival rates of approximately 24 to 30 months in patients not receiving maintenance therapy. There remains a subset of patients, however, who do not respond as well to therapy.

Investigators sought to determine the factors associated with shorter progression-free survival in patients with standard risk multiple myeloma. They reviewed a database of 1750 patients with multiple myeloma who underwent auto-HCT between 2002 and 2010 and identified 61 patients who had a progression-free survival rate of less than 18 months despite upfront auto-HCT.

All had diploid karyotype. Out of the 77% (47 patients) with available fluorescent in-situ hybridization analyses, 83% showed no abnormalities, 11% had monosomy/ or del (13q), 4% had monosomy 13 and t (11; 14), and 2% had trisomy 5.

All patients were treated with a melphalan-based conditioning regimen and there was a median time to auto-HCT of 10 months; 31% of patients received maintenance therapy; and 20% received lenalidomide. After auto-HCT, overall response rate was 93%. Median progression-free survival was 7.7 months and median overall survival was 59.6 months.

Multivariate analysis for variables that showed significance on univariate analysis (P < .05) for progression-free survival determined that patients with concurrent light chain amyloidosis had poorer prognosis (HR, 4.03; 95% CI, 1.16 – 14.06; P = .02). A trend towards poorer progression-free survival was associated with patients who had > 10% bone marrow plasma cells at auto-HCT and monosomy/or del 13 q on fluorescent in situ hybridization (HR, 2.29; 95% CI, 0.85 – 6.15; P = .09; HR, 2.33; 95% CI, 0.86 – 6.31; P = .09). 


1. Badar T, Srour S, Bashir Q, et al. Predictors of inferior clinical outcome in patients with standard risk multiple myeloma. Poster presented at: BMT Tandem Meetings 2016; February 18-22, 2016; Honolulu, HI.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs